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1.0 Executive Summary
1.1 The UK Five Year Antimicrobial Resistance Strategy 2013-2018 is comprehensive with 
respect to the lack of boundaries of antimicrobial resistance (AMR). Successful 
implementation will require a global perspective as outlined within the strategy.
1.2 The three Strategic Aims and seven Key Areas for Future Action are comprehensive and 
plausible. No recommendations for alterations have been suggested.
1.3 Projections based upon historical levels of AMR research funding1 suggest that the 
academic research component of the strategy is not feasible. We propose significant 
increases in AMR-specific funding from the UK government.
1.4 A carefully planned and more thorough public programme focused on the imminent threat 
posed by AMR should be implemented to raise awareness among the general public and 
health professionals. In addition, this public programme should include a component that 
brings the challenge of AMR to the forefront of the attention of researchers and students 
within science, technology, engineering and mathematics (STEM) careers. 
2.0 Introduction
2.1 Dr Roger R. Draheim is a member of the School of Medicine, Pharmacy and Health and a 
Fellow of the Wolfson Research Institute for Health and Wellbeing at Durham 
University. Dr Draheim’s research interests lie in reducing the cost required to discover 
new antibiotics. His work focuses on the application of synthetic bacterial signalling 
pathways in order to develop a next-generation biological platform for high-throughput 
detection of compounds with novel antimicrobial activity.
2.2 The School of Medicine, Pharmacy and Health has an active international research 
programme which emphasises practical issues of translating research into high quality 
care. The Wolfson Research Institute for Health and Wellbeing exists to foster and 
disseminate the wide range of research undertaken at Durham University to improve 
human health and wellbeing. 
2.3 This submission provides the Committee with evidence of current developments in the 
application of synthetic biology to combat increasing antibacterial resistance and 
highlights the advantages of these approaches in enabling the development of new 
antibiotics.
3.0 Research and investment into new antibiotics to ensure continued protection against infection
3.1 Multidrug resistance (MDR) is a frequent problem in several clinical pathogens. In 
Europe, antibacterial-resistant infections kill nearly 25,000 patients and represent a total 
expenditure of approximately £1.5 billion per year.2 However, given the expensive 
research, development and clinical testing required to bring an antibacterial to market, 
coupled with the fact that they are taken for limited time courses and not for life, makes 
them a very unattractive prospect for pharmaceutical companies.
3.2 There is a compelling case to develop new technologies drawing on synthetic biological 
processes in order to reduce the expense associated with discovery of new antibiotics and 
increase accessibility to novel antibacterials. According to the recently published 
Synthetic Biology Roadmap for the UK, the field has the potential to “deliver important 
new applications and improve existing industrial processes – resulting in significant 
economic growth and job creation.”3 The report highlights the UK’s early role in 
responding to opportunities in synthetic biology as well as its international influence. 
3.3 Within this context there is evidence to support the inhibition or overstimulation of two-
component systems (TCSs) as an unrealized mechanism of action to harness novel 
antimicrobials. For example, in several pathogens, host adrenergic signalling molecules, 
such as epinephrine and norepinephrine, have been shown to upregulate1 virulence factor 
expression via the QseC-QseB TCS. LED209, a small molecule compound, has been 
shown to inhibit this upregulation in several animal models.4 Conversely, peptidoglycan 
recognition proteins (PGRPs), which are part of the host innate immune system and 
function in antimicrobial immunity, have been shown to overstimulate the CpxA-CpxR 
system of Escherichia coli and the CssR-CssS system of Bacillus subtilis.5 These two 
studies demonstrate that small molecules that inhibit or overstimulate TCSs are excellent 
candidates for novel antimicrobials.
3.4 TCSs are composed of modular protein domains and allow bacteria to perceive 
environmental stimuli and respond accordingly. To control a diverse array of bacterial 
processes, canonical TCSs must detect a wide variety of stimuli. Within an evolutionary 
context, this has been accomplished by altering its stimulus-sensing properties and DNA-
binding specificity, while leaving the remainder of the TCS scaffold fundamentally 
unchanged. Two-component systems (TCSs) are abundant in bacteria and notably absent 
in humans and other animals, however, they remain largely untapped as potential 
antibacterial targets. Dr Draheim’s current research activity harnesses this conservation 
within a novel “biological screening” platform that physically couples the extracellular 
domains from targeted TCSs to specific intracellular domains that govern precise 
intracellular signalling pathways.
3.5 The QseC, CpxA and CssR proteins described above contain an extracellular domain 
where interaction occurs to inhibit (QseC) or overstimulate (CpxA and CssR) signal 
output to reduce pathogenicity or kill microbial cells, respectively. The proposed 
“biological platform” is derived from rewiring of bacterial signalling circuits by creating 
chimeric receptors composed of an extracellular stimulus-perceiving domain from one 
receptor and the cytoplasmic signalling domain from another (see Section 6.0). The novel 
part of the research is that Dr Draheim’s research group found a way to connect these 
extracellular domains to a well-characterized intracellular domain of a different protein 
(EnvZ). When this well-characterized intracellular domain detects an interaction with the 
extracellular domain, fluorescent genes are transcribed which results in the E. coli cells in 
which the “screening” occurs to fluoresce. This fluorescence can be detected 
1 A process to make pathogens more virulent.
inexpensively, rapidly and in parallel (using a 96-well plate format). For example, this 
allows compounds like LED209 to bind to a chimeric QseC-EnvZ that will cause E. coli 
cells to become fluorescent when LED209 interacts with the extracellular domain 
(derived from QseC) of the chimera. It is important to understand the scalability of this 
technique: Dr Draheim’s research group is explicitly designing this biological platform 
(fluorescent E. coli cells expressing chimeric proteins) to be compatible with the majority 
of TCSs in nature. Currently, roughly 200,000 TCSs have been identified within more 
than 7,500 sequenced microbes resulting in an average of more than 25 targetable TCSs 
per microbe.6,7 
3.6 There are many potential advantages to such an approach, including:
3.6.1 Efficiency and cost: There are already in existence a wide number of 
chemical libraries, including small molecule libraries ranging in size from 
approximately 300 to 1.6 million samples (with the largest of these in 
Ukraine)8. As stated above, an average microbe possesses approximately 25 
TCSs. Therefore, screening entire smaller libraries or smaller selections of 
larger libraries against all TCSs in a pathogenic organism become feasible 
with minimal expense. Using these existing libraries would drastically reduce 
the typical costs associated with identification of novel antimicrobials while 
increasing the rate at which potential antimicrobial targets can be subjected to 
small molecule libraries.
3.6.2 Specificity: One large advantage of this methodology is that only the targeted 
TCSs of interest will provide a response (i.e. only interactions with the 
specific extracellular domain of the chimeric protein will result in the cells 
becoming fluorescent). Standard screening methods result in identification of 
compounds that inhibit microbial growth but usually do not instantly provide 
information about the direct target of the antimicrobial.
3.6.3 Safety: One significant advantage to this methodology is that initial screening 
can be performed in the absence of the pathogenic microbe. This will greatly 
reduce the initial cost of screening because antimicrobial-resistant organisms 
could be screened under general laboratory conditions. As an example, 
Staphylococcus aureus subsp. aureus MRSA252, which has been sequenced 
and possesses 18 TCSs,6,7 create chimeric proteins with an EnvZ intraceullar 
domain as described above and express them in the “biological platform” that  
consists of standard laboratory grade E. coli cells. This allows these 18 TCSs 
to be subjected to small molecule libraries without the need to initially grow 
meticillin-resistant staphylococcus aureusis (MRSA). Subsequently, a 
database of small molecules that demonstrate interaction with the chimeric 
protein in the biological platform, referred to as “hits”, can then be tested 
within the actual MRSA.
4.0 Strengths and weaknesses of the Government’s five year strategy for tackling antimicrobial 
resistance
4.1 Strengths
We believe that the UK Five Year Antimicrobial Resistance Strategy 2013-2018 is well written, 
thorough and precisely detailed. In addition, the strategy captures the importance of AMR to 
human health. Specific examples include:
4.1.1 A clear and succinct statement that few public health issues are of greater 
importance
4.1.2 Identification that AMR is a global issue that requires action at the local, 
regional, national and global levels
4.1.3 A correct statement that AMR cannot be eradicated and that its development 
and spread can only be slowed
4.1.4 Use of an elegant tripartite approach of understanding AMR, conservation 
and stewardship of existing treatments, and stimulation of new antibiotics, 
diagnostics and therapies
4.1.5 A direct statement that this is an ambitious approach and that UK government 
cannot succeed in isolation
4.1.6 Establishment of an interdepartmental High-Level Steering Group (HLSG)
4.1.7 A recommendation that clinicians, veterinarians and other healthcare 
professionals need to work in closer collaboration with industry
4.1.8 Development of a strategy that will bring about fundamental changes in 
approach and capability that will extend well beyond the five-year term.
4.2 Weaknesses
Although the strategy is well-planned and thoroughly considered, and the global ramifications of 
AMR are precisely described, we believe that several weaknesses still exist:
4.2.1 The reasons that negatively affect antimicrobial discovery and development, 
including that fact that it currently takes between 10 and 15 years to bring a 
novel antibiotic to market and that a relatively low commercial return on 
investment relative to other therapies, are not described in detail. Although 
potential remedies to issues are proposed in Sections 4.15 and 4.16 of the 
Strategy, they appear either inadequate to address the financial issues 
underpinning these concerns or operate on a time scale too long to have a 
meaningful impact within the timescale of the strategy (e.g. regulatory 
reform).
4.2.2 The funding totals provided under Section 2.7 of the Strategy, which, 
hopefully are not exhaustive, represent a total expenditure of approximately 
£40m between 2008 and 2015, equates to £5m per year, which is woefully 
inadequate to tackle the required research to effectively combat AMR. When 
employing the FEC (Full Economic Cost) model used by most major research 
universities in the UK, a postdoctoral researcher with no experience costs 
roughly £40K/year, which indicates that he funding described in Section 2.7 
could fund roughly 125 personnel throughout the entire UK over a given 
year.
4.2.3 However, this is not a realistic estimate as it does not consider the costs of the 
required research infrastructure or consumables. From a personal perspective, 
a recent proposal to the BBSRC to fund the research outlined about for 3 
years had a FEC of approximately £500k over three years for a single full-
time postdoctoral researcher. At those rates, the projected £5m will fund 
roughly 35 full-time researchers across the UK.
4.2.4 It should be stated that underfunding of AMR is not a new issue. A 
comprehensive review of research funding concerning infectious disease was 
recently conducted.1 This review found that out of 6,165 funded projects 
representing £2.6b in total expenditure between 1997 and 2010, that only 
£106m (or less than four per cent) was directed at antimicrobial research in 
general, including antiviral and antifungal research (not only resistance to 
antibiotics). Furthermore, when research involving the three most funded 
fields (HIV, tuberculosis and malaria) are removed, that number plummets to 
£62.5m or approximately three per cent of total research funding over the 14 
year period, which when inflation is taken into account, is consistent with the 
roughly £5m/year detailed in Section 2.7 of the strategy. Given my personal 
calculations as detailed above, this should result in approximately 35 full-
time personnel spread throughout the entire UK, which is woefully 
inadequate to address the scientific issues detailed in the strategy.
5.0  Recommendations and action points
We believe that the Government should:
5.1 Continue to follow the outlined strategy as it is well-planned and comprehensive.
 
5.2 Increase research funding to a level that is consistent execution of the outlined research 
strategy. 
5.3 Implement a carefully planned and more thorough public programme focused on the 
imminent threat posed by AMR. In addition, this public programme should include a 
component that brings challenge of AMR to the forefront of the attention of researchers 
and students within STEM careers.
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